Mason, Stephen W.
Pfizer (United States)
3 papers on CoChatORCID 0000-0002-6662-9624
Most cited papers
- Verified
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Cited by 2,033
- Verified
Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
Fader, L. D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., et al. (2014) · ACS Medicinal Chemistry Letters
HIV/AIDS drug development and treatmentHIV Research and Treatment
Cited by 178
- Verified
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Boras, B., Jones, R. M., Anson, B. J., Arenson, D., Aschenbrenner, L., Bakowski, M. A., Beutler, N., Binder, J., Chen, E., Eng, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory)
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Cited by 154
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free